Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer by Kümmel, S et al.
Randomised trial: survival benefit and safety of adjuvant
dose-dense chemotherapy for node-positive breast cancer
SK u ¨mmel*,1, J Krocker
2, A Kohls
3, G-P Breitbach
4, G Morack
5, M Budner
6, J-U Blohmer
1 and D Elling
2
1Department of Gynecology/Obstetrics, University Medicine Berlin, Charite ´ Campus Mitte, Schumannstr. 20/21, Berlin 10117, Germany;
2Krankenhaus
Lichtenberg, Klinik fu ¨r Frauenheilkunde, Fanningerstr. 32, Berlin 10365, Germany;
3Evangelisches Krankenhaus Ludwigsfelde-Teltow, Ludwigsfelde GmbH,
Albert-Schweitzer-Strastr. 42-44, Ludwigsfelde 14974, Germany;
4Staedtisches Klinikum Neunkirchen GmbH, Neunkirchen GmbH, Brunnenstr. 20,
Neunkirchen/Saar D-66538, Germany;
5Helios Klinikum Berlin-Buch, Wiltbergstr. 50, Berlin 13125, Germany;
6Humaine-Klinikum Bad Saarow,
Pieskowerstr. 33, Bad Saarow-Pieskow 15526, Germany
We evaluated the survival benefit, safety, feasibility, and tolerability of dose-dense (DD) adjuvant chemotherapy with epirubicin and
paclitaxel for women with node-positive primary breast cancer. Randomised patients (n¼216) received DD or conventional-
schedule (CS) chemotherapy. Dose-dense regimen patients (n¼108) received epirubicin 90mgm
 2 plus paclitaxel 175mgm
 2 in
four 14-day cycles, then cyclophosphamide 600mgm
 2, methotrexate 40mgm
 2, and fluorouracil 600mgm
 2 (CMF 600/40/600)
in three 14-day cycles, plus filgrastim 5mgkgday
 1 as growth support in every cycle. Conventional-schedule regimen patients
(n¼108) received epirubicin 90mgm
 2 plus cyclophosphamide 600mgm
 2 in four 21-day cycles, then CMF 600/40/600 in three
21-day cycles, plus filgrastim if required. After a median follow-up of 38.4 months, 71 patients (33%) relapsed or died: DD, 33 patients
(15 deaths); CS, 38 patients (22 deaths). Dose dense showed a trend for improved disease-free survival (DFS) and overall survival
(OS). Four-year rates of DFS and OS were 64 and 85% for DD, and 58 and 75% for CS. All seven cycles were administered to 208
patients (96%). Rates of cycle delay, discontinuation, dose reduction, and adverse events were similar in both groups. Dose-dense
sequential chemotherapy with epirubicin/paclitaxel then CMF, supported by filgrastim, is safe and improves survival for patients with
node-positive breast cancer.
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Dose-dense (DD) adjuvant chemotherapy regimens for node-
positive breast cancer limit the opportunity for the regrowth of
cancer cells between chemotherapy cycles and improve disease-
free survival (DFS) and overall survival (OS) compared with
conventional treatment regimens (Wood et al, 1994; Budman
et al, 1998; Citron et al, 2003). For breast cancer tumours that are
resistant to conventional therapy with cyclophosphamide, metho-
trexate, and 5-fluorouracil (CMF), anthracyclines (e.g., doxo-
rubicin or epirubicin) and taxanes (e.g., paclitaxel or docetaxel)
are active and increase survival for many patients (Glu ¨ck, 2001).
Anthracyclines and taxanes have different mechanisms of
action, little overlap in haemotoxicity, and limited crossresistance
(Glu ¨ck, 2001). In clinical studies, sequential administration of
doxorubicin followed by CMF and paclitaxel in combination
with doxorubicin improved survival compared to CMF alone
(Bonadonna, 1996). Epirubicin provides comparable response
rates to those of doxorubicin, with reduced cardiotoxicity at
equivalent doses (Lu ¨ck et al, 1996; Glu ¨ck, 2001). The survival
advantages of epirubicin have been confirmed in several clinical
trials, including 7- and 10-year studies (Early Breast Cancer
Trialists’ Collaborative Group, 1998; Levine et al, 1998; Fumoleau
et al, 2003a,b; Poole et al, 2003; Bonneterre et al, 2005). Recent
evidence suggests that adding taxanes to anthracycline regimens
may further improve patient survival (Henderson et al, 2003;
Roche ´ et al, 2004; Martin et al, 2005).
Using anthracyclines and taxanes in a DD schedule of sequential
combination chemotherapy has been shown to confer a survival
benefit compared to conventional regimens (Glu ¨ck, 2001; Citron
et al, 2003; Mo ¨bus et al, 2004). However, DD therapy carries an
increased risk of febrile neutropenia, a potentially fatal complica-
tion for up to 10% of patients. Neutropenia also may increase the
risk and cost of treatment and result in dose reduction or delay of
planned chemotherapy (Ozer et al, 2000). Studies of dose-intense
regimens demonstrate that delay in the administration of planned
chemotherapy or reduction of doses may be associated with
decreased DFS and OS (Bonadonna et al, 1995; Budman et al, 1998).
Growth factor support in DD chemotherapy regimens can reduce
the incidence of neutropenic complications, thereby facilitating
the administration of a high percentage of chemotherapy doses as
planned (Bonadonna, 1996). Because delivery of planned doses of
chemotherapy is associated with improved survival, DD regimens
often include growth factor support (Bonadonna, 1996; Link et al,
2001; Citron et al, 2003; Mo ¨bus et al, 2004).
Our prospective, randomised multicentre clinical study com-
pares the rates of DFS and OS associated with two adjuvant
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streatment regimens for primary breast cancer in patients with X4
positive lymph nodes: epirubicin and paclitaxel followed sequen-
tially by CMF in a DD schedule, vs a standard regimen of
epirubicin and cyclophosphamide followed sequentially by CMF in
a conventional schedule. The feasibility and tolerability of the
regimens are also compared. Growth factor support was provided
in all cycles to all patients in the DD group, and as needed to
patients in the conventional-schedule (CS) group. Early feasibility
and toxicity data have been reported previously (Elling et al,
2000); this interim report describes DFS, OS, safety, feasibility, and
tolerability after an average of 38.4 months of follow-up.
PATIENTS AND METHODS
Study population
This study was conducted in accordance with the ethical principles
defined in the Declaration of Helsinki of the World Medical
Association. The protocol was approved by each institution’s
ethics committee, and each enrolled patient provided written
informed consent. A total of 231 female patients were enrolled
in the study at 30 centres in Germany between July 1996 and
December 2000. Patients had primary resected, histologically
confirmed breast cancer, stage I, II, or III (Sobin et al, 1997).
Surgical procedures, performed p15 days before randomisation,
included R0 resection and axillary extirpation (levels I to II
obligatory, or level III depending on the clinical situation). Patients
had X4 positive axillary lymph nodes, no distant metastases, an
Eastern Cooperative Oncology Group (ECOG) performance status
o2, adequate organ function, and no previous chemotherapy or
radiotherapy. Exclusion criteria included leucocytes o3.5 10
9l
 1
or platelets o100 10
9l
 1. One patient with an ECOG perfor-
mance status of 3 was admitted to the study in violation of the
protocol; this patient was included in the analysis.
Study design
This multicentre, randomised, open-label Phase 3 adjuvant therapy
optimisation study evaluates a DD sequential chemotherapy
regimen administered after mastectomy or breast-conserving
surgery. The primary end point of the study was the rate of DFS
of patients receiving the two sequential regimens. The secondary
end points were the rates of OS in the two groups, the incidence
of chemotherapy postponement or dose reduction, and the safety
and tolerability of the regimen. The study also examined factors
that may affect DFS, including hormone receptor status, number
of positive lymph nodes, tumour status, malignancy grade, age,
haemoglobin values, and delays in chemotherapy administration.
Eligible patients were randomised in permuted blocks, stratified
by centre, to one of the two chemotherapy treatment groups
(DD-schedule group or CS group) using a computer-generated
randomisation list (Figure 1). The DD-schedule group received
treatment with four cycles of epirubicin and paclitaxel at 14-day
intervals, followed by three cycles of CMF at 14-day intervals.
All patients in the DD-schedule group received filgrastim in each
cycle, administered at a dose of 5mgkgday
 1 beginning on day
5 and continuing until either day 13 or leucocyte counts reached
410 10
9l
 1. The CS group received a conventional sequential
regimen: four cycles of epirubicin and cyclophosphamide at 21-day
intervals followed by three cycles of CMF at 21-day intervals.
Patients in the CS group were treated with filgrastim in subsequent
cycles if they experienced any of the following events during
a cycle: absolute neutrophil count (ANC) o0.5 10
9l
 1 for more
than 2 days, a fever of unknown origin (438.51C), infection, or
the interval between cycles of chemotherapy prolonged by more
than 3 days because of ANC p2.5 10
9l
 1. Assigned chemo-
therapy regimens were initiated no later than 21 days after surgery
(tumour resection or mastectomy) if patients met the study
entry criteria. Patients were required to exhibit haematologic
recovery (ANC X1.0 10
9l
 1 and platelets X50 10
9l
 1) on the
scheduled start day for the next cycle before receiving chemo-
therapy. The initial postponement was 3 days, followed by a
repeated measurement and another postponement, if required, of
3 to 4 days, if haematologic recovery had not occurred.
The treatment phase of the study ended when patients achieved
haematologic recovery after the last administration of chemo-
therapy in accordance with protocol. Patients were followed for up
to 5 years after inclusion in the study with regularly scheduled
visits.
Treatment procedures
At baseline and at the end of the study, patients underwent
physical examinations, including the measurement of baseline
characteristics, disease staging, and performance status, as well as
thoracic radiographs, mammography of the contralateral breast,
and abdominal sonography. Left ventricular ejection fraction was
measured by electrocardiogram or echocardiogram. Other assess-
ments were performed at the investigator’s discretion. Complete
blood counts (CBC) and other appropriate laboratory tests were
also performed. A CBC was obtained twice weekly during treat-
ment. During the period of expected postchemotherapy neutrophil
count nadir, a CBC was taken every 2 days. Electrolytes, creatinine,
and C-reactive protein measurements were taken weekly.
Each group received two sequences of chemotherapy. The DD-
schedule group began the first sequence of epirubicin 90mgm
 2
by short intravenous (i.v.) infusion, followed by a 3-h i.v. infusion
of paclitaxel 175mgm
 2 on day 1, repeated for four cycles at a
planned interval of 14 days. In the second sequence of treatment,
DD-schedule group patients received three cycles of cyclo-
phosphamide 600mgm
 2, methotrexate 40mgm
 2, and 5-fluoro-
uracil 600mgm
 2 (CMF 600/40/600) by short i.v. infusion at a
planned interval of 14 days. The DD-schedule group also received
filgrastim 5mgkgday
 1 in each cycle during both sequences of
chemotherapy. For the CS group, the first chemotherapy sequence
consisted of a short i.v. infusion of epirubicin 90mgm
 2 and cyclo-
phosphamide 600mgm
 2, repeated for four cycles at a planned
interval of 21 days. In the second sequence, the CS group received
three cycles of CMF 600/40/600 by short i.v. infusion at a planned
interval of 21 days. Patients in the CS group could have received
filgrastim if required.
Patients receiving paclitaxel received appropriate premedication
before administration of paclitaxel. Supportive medications were
administered at the investigator’s discretion. Patients who experi-
enced febrile neutropenia were treated according to the standard
operating procedures of each centre. Patients with a fever X381C
who had not received blood products received antibiotic therapy.
Empirical antibiotic therapy in patients with febrile neutropenia
without a positive blood culture was discontinued after the patient
had been afebrile for 72h, provided the neutropenia was resolved.
Platelet transfusions were given when a patient’s platelet count
fell to 15 10
9l
 1 or below. Erythrocyte concentrates were given in
accordance with standard practice at the investigator’s institution.
All supportive measures, treatments for infection, transfusions,
and administrations of erythrocyte concentrate were documented.
All patients with positive oestrogen or progesterone receptor
status received tamoxifen 20mgday
 1 for 5 years. All patients who
had undergone breast-conserving surgery received adjuvant radio-
therapy (40–50Gy) on completion of the chemotherapy.
Statistical analysis
DFS and OS measurements The trial was designed to detect
a difference of 15% (60 vs 75%) in the primary end point of DFS
after 5 years, with a risk of type 1 error of 5% (one-sided) and
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sa power of approximately 80%, based on the planned sample size
of 121 patients in each treatment group. Kaplan–Meier curves
were used to analyse DFS and OS. No interim analyses were
planned or performed, so multiple analyses were not considered.
The randomised and prognostic groups were compared using the
log-rank test (Peto et al, 1977), and hazard ratios were provided
with 95% confidence limits. Unless specifically designated as one-
sided, all P-values are two-sided. Except for the primary end point,
all analyses and statistical tests were performed as descriptive or
exploratory.
Feasibility, safety, and tolerability The feasibility of DD chemo-
therapy in a sequential therapy regimen was measured as the
percent of evaluable chemotherapy cycles that were delayed
from the planned schedule and the percent of postponed cycles
caused by a delay in haematologic recovery. Safety and tolerability
were defined in terms of adverse events during treatment and
follow-up.
Data sets All data for eligible patients were included in the
survival analysis and analysed on the basis of intention-to-treat.
All data for patients who received at least one chemotherapy
cycle were included in the safety and tolerability analysis, except
for two patients for whom haemotoxicity data were not available.
Descriptive or exploratory analyses were performed for the results
included in this report.
RESULTS
A total of 231 women aged 26 to 72 years (mean age, 53 years,
standard deviation (s.d.) 10 years), 60% of whom were post-
menopausal, enrolled at 30 centres between July 1996 and
December 2000. They were randomly assigned to one of two
schedule groups: 116 patients to DD therapy and 115 patients to a
CS regimen. A total of 15 patients were excluded because of
ineligibility. In total, 10 patients were ineligible (five in each
Enrolled patients (N = 231)
Dose-dense regimen Conventional regimen
n = 116 n = 115
Epirubicin 90 mg m
–2 + paclitaxel 175 mg m–2 Epirubicin 90 mg m–2 + cyclophosphamide 600 mg m–2
+
+
+
+
Filgrastim 5 g kg
–1 day, days 5–13 Filgrastim 5 g kg
–1 day, days 5–13 if required
Filgrastim 5 g kg
–1 day, days 5–13 if required Filgrastim 5 g kg–1 day, days 5–13
4 cycles at 14-day intervals 4 cycles at 21-day intervals
3 cycles at 14-day intervals 3 cycles at 21-day intervals
CMF 600/40/600 CMF 600/40/600
Ineligible, n = 8 Ineligible, n = 7
Discontinued, n = 2 Discontinued, n = 1
Discontinued, n = 1
Discontinued, n =  2
Discontinued, n = 1
Discontinued, n = 1
Cycle 1, n = 108 Cycle 1, n = 108
Cycle 2, n = 106 Cycle 2, n = 107
Cycle 3, n = 107
Cycle 4, n = 107
Cycle 5, n = 106
Cycle 6, n = 106
Cycle 3, n = 105
Cycle 4, n = 104
Cycle 5, n = 104
Cycle 6, n = 104
Cycle 7, n = 104
(96%)
Cycle 7, n = 104
(96%)
Figure 1 Study design and patient disposition.
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sgroup) because of a T4 tumour (Sobin et al, 1997). The remaining
five patients were ineligible for the following reasons: existing
metastasis, history of malignant melanoma, previous chemo-
therapy or radiotherapy, tumour activity with uncertain breast
cancer histology, and erroneous chemotherapy administration.
The remaining 216 patients entered the study (108 in each treat-
ment group). One patient refused further treatment after cycle 1
(Figure 1).
Of the 231 patients enrolled, 216 (94%) were evaluated for
efficacy and safety. Patient and disease characteristics in each
treatment group are summarised in Tables 1 and 2. While the
original study design excluded patients with 49 positive lymph
nodes, the protocol was subsequently amended to permit 48
patients with 49 lymph nodes to be included in the study (26
(24%) in the DD-schedule group, 22 (20%) in the CS group).
Disease-free survival
At a median follow-up of 38.4 months, 71 patients (33%)
experienced a first event of relapse or death, including 33 events
(31%) in the DD-schedule group and 38 events (35%) in the CS
group.
The DFS rate after 2 years was 81% (95% confidence limits (CL),
74–89%) in the DD-schedule group and 72% (64–81%) in the CS
group. After 4 years, the DFS rate was 64% (55–76%) in the
DD-schedule group and 58% (48–70%) in the CS group. There was
trend for DFS in favour of the DD-schedule group, although the
difference was not significant (log-rank test, one-sided P¼0.12)
(Figure 2). The hazard ratio, with the DD-schedule group as
reference, was 1.32 (0.82 to 2.11) at the time of this analysis. The
most common site of disease relapse was bone metastasis (31% of
cases), followed by metastasis at local sites, including chest wall,
thoracic wall, and axillary and infraclavicular lymph nodes (23%).
Overall survival
At a median follow-up duration of 38.4 months, 37 (17%) of 216
patients have died, including 15 patients (14%) in the DD-schedule
group and 22 (20%) in the CS group (Figure 3). The OS rate after
2 years was 94% (89–99%) in the DD-schedule group and
92% (87–97%) in the CS group. After 4 years, the OS rate was
85% (78–94%) in the DD-schedule group and 75% (66–85%) in
the CS group (Figure 3). The hazard ratio, with the DD-schedule
group as reference, was 1.76 (CL 0.91–3.38; log-rang test, two-
sided P¼0.092), suggesting a possible increased risk of death for
patients receiving the CS regimen.
Feasibility (dose reduction or cycle delay)
A total of 1480 cycles of chemotherapy were administered (735
in the DD-schedule group and 745 in the CS group), and 96%
of patients in both groups received all seven cycles. The mean
(s.d.) cycle length was 14.7 days (3.5) for the DD-schedule group
and 21.3 days (1.9) for the CS group.
Commencement of chemotherapy was delayed by more than
1 day in only 10% of DD cycles and 7% of CS cycles. Cycle delays
because of delayed haematologic recovery were slightly more
common in the DD group (12 cycles, 17%) than in the CS group
(six cycles, 12%). Administrative reasons and infection caused
most postponements in the other 85% of delayed cycles. No
reasons for delayed cycles were reported for two patients.
Doses were reduced in 14 of 1477 evaluable cycles (1%), with
no notable differences between groups. (Three cycles were not
evaluable because data about dose reductions and delays were
missing.) Dose reduction resulting from haematologic toxicity
occurred in only one cycle, in the DD-schedule group. In most
other cases, doses were reduced because of weight loss resulting in
decreased body surface area.
Safety and tolerability
The safety and tolerability of the two regimens were similar, as
assessed by discontinuation and interruption of therapy, labora-
tory values, and adverse events. The rate of discontinuation was
the same (4%) in both treatment groups. One patient in the CS
group died during therapy, and one patient in the DD-schedule
Table 1 Patient characteristics in each treatment group
Dose-dense-schedule group Conventional-schedule group Total
Patients randomised (n) 116 115 231
Not eligible (n)8 7 1 5
Evaluated for efficacy (n) 108 108 216
Age (years) (mean (s.d.))
a 53.3 (9.8) 52.5 (9.8) 52.9 (9.8)
o30 years (n (%)) 2 (2%) 0 (0%) 2 (1%)
30–39 years (n (%)) 10(10%) 14 (13%) 24 (11%)
40–49 years (n (%)) 19 (18%) 30 (28%) 49 (23%)
50–59 years (n (%)) 48 (46%) 36 (34%) 84 (40%)
60–69 years (n (%)) 23 (22%) 25 (23%) 48 (23%)
X70 years of age 2 (2%) 2 (2%) 4 (2%)
Menopause status at diagnosis
b
Premenopausal (n (%)) 42 (39%) 44 (41%) 86 (40%)
Postmenopausal (n (%)) 65 (61%) 63 (59%) 128 (60%)
Activity status at diagnosis
c (Oken et al, 1982)
ECOG 0 (n (%)) 89 (86%) 87 (84%) 176 (85%)
ECOG 1 (n (%)) 12 (12%) 16 (15%) 28 (14%)
ECOG 2 (n (%)) 1 (1%) 1 (1%) 2 (1%)
ECOG 3 (n (%)) 1 (1%) 0 (0%) 1 (0%)
Patients undergoing surgery (n) 108 108 216
Breast conserving (n (%)) 42 (39%) 46 (43%) 88 (41%)
Mastectomy (n (%)) 66 (61%) 62 (57%) 128 (59%)
ECOG¼Eastern Cooperative Oncology Group.
aNo date of birth given for five patients.
bNo menopause status given for two patients.
cNo activity given for nine patients.
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sgroup refused further treatment after receiving first-cycle therapy.
Two patients (2%) in the DD-schedule group and one patient (1%)
in the CS group discontinued because of toxicity, including
acute hypersensitivity reactions, febrile neutropenia, and fatigue.
Three patients (one in the DD-schedule group, two in the CS
group) discontinued for other reasons, including withdrawal of
consent, uncontrolled diabetes, and infection of a breast wound.
Of 1477 evaluable chemotherapy cycles administered, nine
infusions (o1%) had interruptions from 10min to 24h (733
cycles in the DD-schedule group, 744 cycles in the CS group). One
patient in the DD-schedule group experienced an acute hyper-
sensitivity reaction to paclitaxel, and therapy was discontinued.
Reasons for interruption included burning sensations at the
infusion site, paravasation, and a defective container.
Haematologic toxicity Filgrastim was administered to all patients
in the DD-schedule group in every cycle. In the CS group,
filgrastim was administered in 111 of 745 cycles (14.9%), on
an as-needed basis. Leukopenia and neutropenia occurred in
both treatment groups at similar rates (Table 3). No patients
experienced grade 4 anaemia or grade 4 thrombocytopenia. Grade
3 anaemia and grade 3 thrombocytopenia were rare in both
groups. Analysis of haematologic toxicity on the basis of cycles
yielded similar results.
Nonhaematologic toxicity The most frequently reported non-
haematologic adverse events were alopecia, nausea, and vomiting
(Table 3). Fatigue, mucositis, bone pain, and peripheral nervous
system (PNS) toxicity were also frequently reported. The incidence
of nonhaematologic toxicity was similar in both treatment groups,
except for one adverse event commonly associated with paclitaxel
and two adverse events commonly associated with filgrastim.
Events that occurred more often in the DD-schedule group than
the CS group include PNS toxicity (47 vs 11%), bone pain (44 vs
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Figure 2 Disease-free survival.
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Figure 3 Overall survival.
Table 2 Disease characteristics in each treatment group
Dose-dense-schedule group Conventional-schedule group
Age p50 years
(n¼34)
Age 450 years
(n¼70)
Age p50 years
(n¼45)
Age 450 years
(n¼62)
Total
n¼211
a
Oestrogen hormone receptor status
b
(n)
34 70 44 62 210
Positive (n (%)) 22 (65%) 50 (71%) 32 (73%) 50 (81%) 154 (73%)
Borderline or threshold (n (%)) 1 (3%) 5 (7%) 1 (2%) 3 (5%) 10 (5%)
Negative (n (%)) 10 (29%) 14 (20%) 10 (23%) 9 (15%) 43 (20%)
Not determined (n (%)) 1 (3%) 1 (1%) 1 (2%) 0 (0%) 3 (1%)
Histopathological grade
c (n) 34 69 43 62 208
G1 (n (%)) 1 (3%) 5 (7%) 2 (5%) 4 (6%) 12 (6%)
G2 (n (%)) 15 (44%) 35 (51%) 16 (37%) 33 (53%) 99 (48%)
G3 (n (%)) 18 (53%) 29 (42%) 25 (58%) 25 (40%) 97 (47%)
Tumour stage (n) 34 70 45 62 211
T1 (n (%)) 8 (24%) 24 (34%) 13 (29%) 15 (24%) 60 (28%)
T2 (n (%)) 20 (59%) 33 (47%) 26 (58%) 33 (53%) 112 (53%)
T3 (n (%)) 6 (18%) 13 (19%) 6 (13%) 13 (21%) 38 (18%)
T4 (n (%)) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
TX (n (%)) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 1 (0%)
Nodal stage (n) 34 70 45 62 211
N1 (n (%)) 29 (85%) 63 (90%) 43 (96%) 54 (87%) 189 (90%)
N2 (n (%)) 5 (15%) 6 (9%) 2 (4%) 8 (13%) 21 (10%)
N3 (n (%)) 0 (0%) 1 (1%) 0 (0%) 0 (0%) 1 (0%)
Lymph node status (n) 34 70 45 62 211
4–9 involved nodes (n (%)) 27 (79%) 51 (73%) 40 (89%) 45 (73%) 163 (77%)
49 involved nodes (n (%)) 7 (21%) 19 (27%) 5 (11%) 17 (27%) 48 (23%)
aNo date of birth given for five patients.
bNo hormone receptor status given for one patient.
cNo malignancy grades given for three patients.
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s23%), and arthralgia/myalgia (22 vs 15%). Grade 3 cardiotoxicity
was extremely rare (one patient in the CS group, none in the DD-
schedule group); no patients experienced grade 4 cardiotoxicity.
Other potential predictors of survival
The effects on DFS of hormone receptor status, menopausal status,
number of positive lymph nodes, primary tumour status (T-stage),
malignancy grade, age, haemoglobin value, and delays in chemo-
therapy cycles were also analysed.
Oestrogen hormone receptor status (Figure 4) Negative or border-
line hormone receptor status had a negative effect on DFS that
was statistically significant (two-sided P¼0.0044). After 2 years,
patients with a negative or borderline hormone receptor status had
a 62% (50–77%) DFS rate compared with an 82% (76–89%) DFS
rate for hormone-receptor-positive patients. After 4 years, the DFS
rate for hormone receptor-negative or borderline patients was 48%
(35–66%) compared with a 66% (57–75%) DFS rate for hormone-
receptor-positive patients. While the data in Figure 4 suggest that
patients with negative hormone receptor status profit most from
DD therapy, the small sample size warrants a cautious interpreta-
tion of this analysis.
Menopausal status Menopausal status had no significant effect
on DFS in this study.
Number of positive lymph nodes (Figure 5) The prognostic utility
of axillary lymph node status in primary breast cancer was confir-
med in this study (two-sided P¼0.017). After 2 years, patients
with 49 positive lymph nodes had a DFS rate of 68% (56–83%)
compared with 79% (73 to 86%) for patients with 4 to 9 positive
lymph nodes. After 4 years, patients with 49 positive lymph nodes
had a DFS rate of 48% (35 to 65%) compared with 66% (57 to 75%)
for patients with four to nine positive lymph nodes. Patients in
the DD-schedule group who had 49 positive lymph nodes had
a survival advantage compared to patients with 49 positive nodes
in the CS group (Figure 5). As with hormone receptor status,
this subgroup analysis should be interpreted with caution because
of the small sample size.
Tumour status (T-stage) The stage of the tumour at the time
of diagnosis was also a predictor of DFS, with tumours 45cm
showing a clearly less favourable prognosis (two-sided P¼0.0057).
At 2 years, patients with stage T1 tumours had an 85% DFS
rate (76–94%) compared with 78% (70–86%) for patients with
stage T2 tumours and 64% (50–82%) for patients with stage T3
tumours. After 4 years, DFS was 76% (64–90%) for patients with
stage T1 tumours, 62% (52–73%) for patients with stage T2
tumours, and 40% (26–62%) with stage T3 tumours.
Malignancy grade Malignancy grade was not as strong a predic-
tor of DFS as tumour stage, but differences between malignancy
Table 3 Haematologic and nonhaematologic toxicity: highest WHO grade for each patient
Toxicity
Dose-dense-schedule group Conventional-schedule group
WHO grade
a (n (%)) WHO grade
a (n (%))
n 0 1 or 2 3 4 n 0 1 or 2 3 4
Haematologic
Leukopenia 108 10 (9%) 50 (46%) 40 (37%) 8 (7%) 107 8 (7%) 47 (44%) 46 (43%) 6 (6%)
Neutropenia 77 9 (12%) 20 (26%) 26 (34%) 22 (29%) 82 12 (15%) 17 (21%) 23 (28%) 30 (37%)
Thrombocytopenia 107 82 (77%) 22 (21%) 3 (3%) 0 107 97 (91%) 10 (10%) 0 0
Anaemia 108 14 (13%) 90 (83%) 4 (4%) 0 107 42 (39%) 64 (60%) 1 (1%) 0
Nonhaematologic
Alopecia 108 6 (6%) 16 (15%) 86 (80%) 0 107 4 (4%) 14 (13%) 89 (83%) 0
Nausea/vomiting 108 14 (13%) 87 (81%) 7 (6%) 0 107 10 (9%) 85 (79%) 11 (10%) 1 (1%)
Fatigue 108 42 (39%) 58 (54%) 8 (7%) 0 107 52 (48%) 52 (49%) 3 (3%) 0
Mucositis 108 57 (53%) 42 (39%) 9 (8%) 0 107 60 (56%) 45 (42%) 2 (2%) 0
Bone pain 108 60 (56%) 43 (40%) 5 (5%) 0 107 82 (76%) 22 (21%) 2 (2%) 1 (1%)
PNS toxicity 108 57 (53%) 50 (46%) 1 (1%) 0 107 95 (88%) 11 (10%) 1 (1%) 0
Arthralgia/myalgia 108 84 (78%) 20 (19%) 4 (4%) 0 107 91 (84%) 16 (15%) 0 0
PNS¼peripheral nervous system; WHO¼World Health Organization.
aBecause of rounding, percentages may not total 100%.
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sgrades were statistically significant (two-sided P¼0.046). After
2 years, patients with grade G1 or G2 had a DFS rate of 81%
(74–89%) compared with 71% (62–81%) for grade G3 malig-
nancies. After 4 years, patients with G1 or G2 malignancies had
a DFS rate of 67% (56–78%) compared with 53% (43–66%) for
patients with G3 malignancies (Figure 6).
Age As expected, there was a trend toward a less favourable
outcome for younger patients, although the trend was not statis-
tically significant. After 2 years, patients X50 years of age had a
DFS of 80% (73–87%) compared with 71% (62 to 83%) for patients
o50 years. After 4 years, results were similar; patients X50 years
of age had a DFS of 63% (54–73%) compared with 57% (45–73%)
for patients o50 years.
Haemoglobin values It has been proposed that a low haemo-
globin value is associated with a less favourable prognosis. Interim
results from this study do not support this hypothesis, either
for a baseline haemoglobin o12gdl
 1 or for a haemoglobin nadir
o11gdl
 1 during therapy (data not shown).
Chemotherapy cycle delay Although several studies have shown
that a delay in administration of chemotherapy cycles negatively
affects DFS, that effect was not significant in this study. The small
number of cycle delays X2 days (eight in each treatment group)
warrants caution in interpreting these results.
DISCUSSION
Advances in treatment strategies for node-positive breast
cancer include the identification of the chemotherapy agents
(including epirubicin and paclitaxel) that are active against
tumours resistant to CMF therapy. This study demonstrates
that combining epirubicin and paclitaxel followed by CMF in
DD adjuvant chemotherapy is feasible, safe, and tolerable for
most patients, and that this combination appears to improve OS
and DFS in node-positive breast cancer compared with conven-
tional treatment schedules using epirubicin and cyclo-
phosphamide. The use of filgrastim support to prevent neutropenia
enhances the safety and tolerability of this regimen. It may also
contribute to the rarity of cycle delays in chemotherapy adminis-
tration in this study.
Discontinuations, cycle delays, and dose reductions were
few, which may reflect the lower toxicity of epirubicin and the
myeloprotective effects of filgrastim. Peripheral neuropathy,
bone pain, and arthralgia/myalgia, which were more common
in the DD treatment group, are associated with both paclitaxel
and filgrastim; the design of this study does not permit a direct
association of these side effects with a single drug.
The benefit of DD therapy for patients with four or more
positive axillary nodes is consistent with that seen in Cancer and
Leukaemia Group B (CALGB) study 8541 (Wood et al, 1994),
but the treatment regimen used in our study resulted in some-
what higher DFS rates; in CALGB study 8541 of treatment with
cyclophosphamide, doxorubicin, and 5-fluororacil, patients with
X4 positive nodes who received high-dose therapy had a DFS
rate of 67% after 3 years compared with 62% for a DD therapy
schedule and 46% for low-dose therapy. In comparison, 4-year
DFS rates in our study were 64% for the DD-schedule group and
58% for the CS group. In CALGB study 8541, patients with X10
positive nodes fared worst, but still did better with DD therapy
than with low-dose therapy (44% DFS rate after 3 years with
high-dose or DD therapy vs 29% for low-dose therapy) (Wood
et al, 1994). The treatment regimens in our study resulted in a DFS
rate of 48% (35–65%) for patients with X10 positive nodes after
4 years, a modest improvement over the CALGB 8541 results.
Results of this study are similar to those reported in the German
AGO study, in which estimated 3-year DFS rates were 80% (DD
group) and 70% (CS group) for patients with X4 positive lymph
nodes receiving regimens of epirubicin, paclitaxel, and cyclo-
phosphamide. (Mo ¨bus et al, 2004). OS rates in the AGO study were
also comparable to those observed in this study (Mo ¨bus et al,
2004).
In our study, patients with negative hormone receptor status or
49 positive lymph nodes, who have a generally poorer prognosis,
benefited from the DD treatment schedule (Figures 4 and 5). At the
same time, because patients with 49 lymph nodes fared worse
than patients with p9 positive lymph nodes, the inclusion of these
patients in the study reduced the OS and the DFS of the total
patient population. The potential effect of the number of lymph
nodes on survival can be seen by comparing the population in our
study with that in the C9741 study (Citron et al, 2003). In C9741,
59% of the patients had one to three positive lymph nodes, while
all patients in our study had at least four positive lymph nodes.
Only 12% of patients in the C9741 study had 10 or more positive
nodes compared with 22% of the patients in our study. The 4-year
DFS in the C9741 study was 82% for patients receiving DD therapy
compared with 64% for patients receiving DD treatment in our
study.
In the C9741 study, the DD regimen significantly reduced the
incidence of contralateral breast cancer (0.3 vs 1.5%, P¼0.0004)
(Citron et al, 2003); our study did not confirm that finding, as
three patients in each treatment group had contralateral breast
cancer. While recent studies of epirubicin-based regimens have
shown higher OS and DFS rates than those reported here (Citron
et al, 2003; Henderson et al, 2003; Poole et al, 2003), our study is
unique in its demonstration of survival benefits for patients with
X4 positive axillary lymph nodes.
The results of this prospective, randomised multicentre study
provide further evidence that a DD therapy combining anthra-
cyclines with paclitaxel or cyclophosphamide, supported by
filgrastim from the first cycle of chemotherapy, can prolong OS
and DFS in high-risk patients.
As this is an interim report of a relatively small patient
population, caution must be exercised in the interpretation of
these results. Fewer patients were originally enrolled than origi-
nally planned, potentially reducing the statistical power of the
study. Additionally, because of logistic concerns, this regimen may
not be feasible in all countries or hospitals. Finally, the risk of
leukaemia or myelodysplasia consequent to growth factor therapy
must be considered, even though this risk appears to be low and
not limited to DD regimens. Hudis et al reported an incidence
of leukaemia or myelodysplasia p1% in DD and conventional
treatment groups after a median 6.5 years of follow-up in the
C9741 study. (Ozer et al, 2000; Hudis et al, 2005). Analysis of
mature data at a mean follow-up of 5 years will shed additional
light on the selection of an optimum therapy.
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